<DOC>
	<DOCNO>NCT02912156</DOCNO>
	<brief_summary>A Randomized , Parallel , Single-Dose Study Evaluate Pharmacokinetics Two Different Formulation Voriconazole 200 mg Tablets Healthy Adult Subjects .</brief_summary>
	<brief_title>Pharmacokinetics Two Different Formulation Voriconazole</brief_title>
	<detailed_description />
	<mesh_term>Mycoses</mesh_term>
	<mesh_term>Voriconazole</mesh_term>
	<criteria>1 . Healthy adult , age 20 45 year old . 2 . Physically mentally healthy subject confirm interview , medical history review , clinical examination , laboratory test , chest xray electrocardiogram ( ECG ) . No clinically significant find clinical examination laboratory test within two month ( 60 day ) prior administration study medication ; Normal clinically significant discretion investigator chest Xray ECG result within six month ( 180 day ) prior administration study medication . 3 . Body weight 50 kg male 45 kg female . 4 . The body mass index 18 27 ; body mass index equal [ weight ( kg ) ] / [ height ( ) ] 2 . 5 . Laboratory determination result within normal range consider clinically significant investigator , include : Serum Glutamic Oxaloacetic Transaminase ( SGOT , AST ) , Serum Glutamic Pyruvic Transaminase ( SGPT , ALT ) , albumin , glucose , creatinine , uric acid , cholesterol , Triglycerides ( TG ) , GammaGlutamylTranspeptidase ( Î³GT ) , alkaline phosphatase , total bilirubin , Blood Urea Nitrogen ( BUN ) , Hepatitis B surface antigen ( HBsAg ) , AntiHepatitis C virus ( AntiHCV ) AntiHuman Immunodeficiency Virus ( AntiHIV ) test . 6 . Hematology test result within normal range consider clinically significant investigator , include : hemoglobin , hematocrit , White Blood Cell ( WBC ) count , Red Blood Cell ( RBC ) count , platelet count WBC count differential . 7 . Urinalysis result within normal range consider clinically significant investigator , include : glucose , protein , RBC , WBC , epith , cast bacteria . 8 . Adequate contraceptive method must use two week prior two week administration study medication . 9 . Female subject : Using adequate contraception since last menstruation plan conception study . Nonlactating . Had negative pregnancy test ( urine ) prior study . 10 . Informed consent form sign . 1 . A history drug alcohol abuse within 24 week prior study . 2 . History drug allergy , allergic constitution , asthma retinal disease . 3 . Myopia worse 6.0 diopter . 4 . A clinically significant illness ( hematological malignancy ) within past 4 week 5 . Evidence clinical significant renal , cardiovascular , hepatic , hematopoietic , neurological , pulmonary gastrointestinal disease within past 4 week . 6 . Planned vaccination study . 7 . Participation clinical investigation last 60 day . 8 . Regular use medication last 4 week . 9 . Single use medication last 2 week . 10 . Blood donation 250 mL within past 12 week . 11 . Individuals judge investigator undesirable subject .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Pharmacokinetic</keyword>
</DOC>